GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Talphera Inc (NAS:TLPH) » Definitions » Other Net Income (Loss)

TLPH (Talphera) Other Net Income (Loss) : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Talphera Other Net Income (Loss)?

Talphera's Other Net Income (Loss) for the three months ended in Dec. 2024 was $0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Talphera's annual Other Net Income (Loss) increased from Dec. 2022 ($-11.37 Mil) to Dec. 2023 ($-8.11 Mil) and increased from Dec. 2023 ($-8.11 Mil) to Dec. 2024 ($0.00 Mil).


Talphera Other Net Income (Loss) Historical Data

The historical data trend for Talphera's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talphera Other Net Income (Loss) Chart

Talphera Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -11.37 -8.11 -

Talphera Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 - - - -

Talphera Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Talphera Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Talphera's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Talphera Business Description

Traded in Other Exchanges
Address
1850 Gateway Drive, Suite 175, San Mateo, CA, USA, 94404
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Executives
Vincent J. Angotti director, officer: Chief Executive Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Raffi Asadorian officer: Chief Financial Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Pamela P Palmer director, officer: Chief Medical Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Jill Marie Broadfoot director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marina Bozilenko director C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Adrian Adams director C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Mark G Edwards director ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020
Badri N Dasu officer: Chief Engineering Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Lawrence G Hamel officer: Chief Development Officer C/O ACELRX PHARMACEUTICALS INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Mark A Wan director, 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Associates Iii Lp 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028
Wilfred E Jaeger 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Partners Iii Lp 10 percent owner
Three Arch Partners Iv Lp 10 percent owner
Three Arch Associates Iv Lp 10 percent owner 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028